ArticleFrontiers in oncology2026
NONO modulates tumorigenesis and metastatic potential of lung squamous cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung squamous cell carcinoma (LUSC) is associated with limited therapeutic options and poor clinical prognosis. The Octamer nucleotide--binding transcription factor (NONO), which lacks the POU domain, is implicated in nearly every aspect of gene regulation. It participates in various biological processes including cell proliferation, apoptosis, migration, and DNA damage repair. In this study, we report elevated expression of the NONO gene in LUSC as identified through tumor databases. Our biological function experiments confirmed that NONO promotes the proliferation of LUSC cells by inhibiting apoptosis and enhances the tumor cells' capabilities for invasion and metastasis. Through the mediation of the PI3K/AKT signaling pathway, NONO regulates downstream molecules such as FOXO1 and GSK3β, which are related to cell proliferation and apoptosis. It participates in the regulation of LUSC cell proliferation, invasion and metastasis, and can serve as a potential clinical target for LUSC, providing ideas for exploring new treatment methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.